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The polyamines are low molecular weight organic cations which are widely 
distributed in biological systems. They occur in virtually every animal 
and plant tissue in which they have been sought, and in most micro- 
organisms as well. Levels of polyamines markedly rise in cells (in¬ 
cluding tumor cells) during growth, and polyamines have a variety of 
well-characterized effects on nucleic acids in vitro. Recently, a 
body of evidence has accumulated implicating these molecules in the 
mechanisms of hormone actions on target tissues. While their true 
physiological role remains undefined, polyamines appear to be important 
in the regulation of nucleic acid and protein metabolism. 
Historical aspects 
The polyamines of greatest biological significance are spermi¬ 
dine and spermine, aminopropyl derivatives of the diamine, putrescine. 
In the same letter to the Royal Society in 1677 in which he described 
human spermatozoan "animalcules", Leewenhoek reported observing the grad¬ 
ual formation of colorless crystals in semen which were probably sper- 
103 
mine phosphate. These crystals were rediscovered in 1791 by Vaquelin, 
who was apparently unaware of Leewenhoek’s observations, and were studied 
in turn by Boettcher, Charcot, Schreiner, and Poehl, each of whom be¬ 
came affiliated by name with the substance; by the end of the 19th cen¬ 
tury spermine was known by no less than ten names.24,138,181 poepi 




organs; he also promoted his "Sperminum Poehl" commercially as a cure 
for cholera and other conditions (the material actually contained only 
traces of spermine.) ^^ It was not until the work of Rosenheim and as¬ 
sociates, and Wrede, in the 1920's, that the correct structure of sper¬ 
mine was elucidated and confirmed by synthesis.31>153,198 However, for 
the next two decades, scientific attention was focused on the amino acids 
and away from these polyamines which were presumed to be mere products of 
amino acid catabolism. The discovery by Herbst and Snell in 1949 of 
a polyamine-requiring mutant of Hemophilus parainfluenza again stimu- 
r /: 
lated interest in the biological role of these compounds. Improved 
quantitative assays and chromatographic separation techniques followed 
in the 1950's. Subsequent work implicated polyamines in the regula¬ 
tion of cellular growth and nucleic acid metabolism. 
Although seminal fluid occupies a special place in the history of 
the polyamines, little is still known of their function there. Spermine 
(at 5 to 50 mM, the predominant polyamine in semen) is probably not es- 
sential to sperm motility and survival. However, semen does contain 
/: r 
a diamine oxidase which oxidizes spermine to a bacteriostatic aldehyde. 
The bull has no prostate to secrete polyamines, and bull semen, contain¬ 
ing less than 1% as much spermine as human semen, is notoriously infected 
with microorganisms including gonococci.^ Incidentally, these oxidized 
products of spermine may impart to human semen its peculiar odor, des¬ 
cribed by John Hunter in 1786 as "mawkish and unpleasant, exactly 
resembling that of a Spanish chestnut. 
Polyamine Biosynthesis 
Synthesis of polyamines in both prokaryotes and eukaryotes 
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proceeds from amino acids. Probably the rate-limiting step in mammalian 
polyamine synthesis (and the only biosynthetic step proceeding from 
ornithine) is the decarboxylation of L-ornithine to form putrescine and 
carbon dioxide (Figure 1), catalysed by ornithine decarboxylase (ODC) 
(EC 4.1.1.17).^^^ Ornithine is provided by the action of arginase on 
arginine, even in cells lacking other urea cycle enzymes. E. coli and 
mycobacteria can synthesize putrescine from arginine via agmatine, in 
addition to the ODC route.^6 a further detour from agmatine through 
N-carbamoyl putrescine is followed by certain higher plants.How- 
193 
ever, neither of these latter alternatives is important in mammals. 
Putrescine accepts an aminopropyl group from decarboxylated 
S-adenosyl methionine (SAM) to form spermidine. (This respresents an 
unique role for SAM, which is well-known as a methyl donor in prokaryotic 
transmethylations.) The first step in this sequence is the activation 
of L-methionine by coupling with ATP to give SAM, which is next decarb¬ 
oxylated and finally relieved of its aminopropyl group. Spermine is in 
turn formed by the addition of an aminopropyl group to spermidine; sper¬ 
mine is not synthesized by prokaryotes. SAM-decarboxylase, spermidine 
synthase, and spermine synthase now appear to be three easily separable 
enzymes, ^4 contrary to earlier suggestions that a single enzyme complex 
performed all three functions. 24,137,181 decarboxylation of SAM is 
markedly stimulated by putrescine, less so by spermidine, in eukaryotes; 
no such effect is observed in prokaryotes. ^ > ^7 
The work of Gale and of Morris and Pardee revealed two kinds 
of _E. coli ODC: an induced, catabolic enzyme, and a constitutive, bio- 
43 171 
synthetic enzyme, differing in heat stabilities and pH optima, ’ 
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However, mammalian ODC from numerous sources are all alike, resembling 
the rat liver ODC in the following properties: 
1. product inhibition, to various degrees, by putrescine, 
spermidine, and spermine;1^2,136,195 
2. a Km for ornithine of about 0.1 - 0.2 mM,^,143,193 and 
14 3 
specificity for L-ornithine; 
3. a requirement for pyridoxal phosphate but not for cations, 
14 3 
and inhibition by isonicotinic acid hydrazide; 
4. a tendency to polymerize to a catalytically inert form in 
Q O O T I Q C 
the absence of thiol compounds. ’ > Dithiothreitol displays a 
paradoxical effect in that at high concentrations it competitively 
inhibits the enzyme. Mercaptoethanol, at similarly high concentrations, 
41 
maintains a consistent level of activation. 
5. a pH optimum around 7.4 - 8.1 This optimum was originally 
reported to shift to the more alkaline side with higher mercaptoethanol 
concentrations^^ but this does not occur with the purified enzyme.^1 
Most studies on ODC, however, use the crude enzyme. 
Both ODC and SAM-decarboxylase are soluble, but their normal 
intracellular localizations are unknown. In stimulated rat liver, 90% 
of ODC activity-*-^" and 50% of SAM-decarboxylase activity-*-^ are found 
in the soluble fraction of the cell, the remainder of activity being 
mainly nuclear with 2 to 3% microsomal. 
Regulation of ODC Activity 
ODC displays characteristics, particularly a short half-life, 
which suggest tight cellular control over enzyme activity. Russell 
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and Snyder obtained a half-life of 10 to 11 minutes for liver ODC by 
testing activity at short time intervals after injecting cycloheximide 
or puromycin into partially hepatectomized rats,^7,1^2 or CyCloheximide 
into rats pretreated with growth hormone'*"'^ or 17 3-estradiol. jn a 
separate experiment in which no inhibitors of protein synthesis were 
used, growth hormone was administered and the half-life was calculated 
from the downslope of the ODC activity curve to be 24 minutes.1^9 As 
this latter figure is probably an overestimate, it confirms the finding 
that ODC has the fastest turnover of any mammalian cellular enzyme yet 
characterized. These figures compare with a t^ of 67 to 72 minutes for 
6-amino levulinic acid synthetase (previously thought to be the enzyme 
with the briefest activity); 2.0 hours for ribonucleotide reductase; 
17? 
and 4 to 5 days for arginase. 
Several mechanisms may explain the swift decline in ODC activity. 
In two animal systems recently studied, the half-life of ODC changed 
rapidly together with total enzyme activity, with the half-life greatest 
in stimulated cells undergoing division and shortest in inhibited 
cells. 5°u Thus enzyme inactivation might be important in the regula¬ 
tion of ODC activity. Inactivation may come about through an energy- 
requiring degradation of enzyme protein, as is suggested by the finding 
that dinitrophenol lengthens the half-life of ODC in insulin-stimulated 
mammary tissue from 18 minutes to one hour. Putrescine, spermidine, and 
spermine have recently been shown to induce the synthesis by cultured 
rat hepatoma cells,^ mouse leukemia cells, and neuroblastoma cells'^ 
of a protein (dubbed an "antizyme") which non-competitively inhibits ODC 
from each of these sources. This observation is exciting in that the 
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"antizyme" appears to represent a previously undiscovered mechanism for 
enzyme regulation. This mechanism might also explain the earlier ob¬ 
servation that the injection of putrescine^ ’165 Qr Spermicjine70 
specifically prevent the rise in ODC activity in regenerating rat 
liver, and that putrescine or spermidine block the ODC rise in cul¬ 
tured 3T3 cells. 
Among the other factors which have been found to affect ODC 
activity are microtubular structure^ and changes in cellular cation 
21 
pools. Putrescine, and to lesser degrees spermidine and spermine, 
are weak competitive inhibitors of ODC.^^2,136,195 
It has been widely suspected that cte novo synthesis of enzyme 
protein plays a role in cellular control of ODC activity, based mainly 
on findings in numerous systems that inhibitors of protein or RNA syn¬ 
thesis will prevent the stimulatory response of enzyme activ¬ 
ity; 131,149,202 tjlus has bggH proposed that polyamines block 
ODC stimulation by selective inhibition of the translation of the 
O T 1 Of. 
enzyme. 0,100 Early work with antibodies to rat liver ODC has lent 
support to this speculation.18,62,187 
Polyamines and Growth 
The conditions under which polyamine levels are observed to 
rise suggest a relationship between these amines and growth processes. 
In man and other animals, tissue putrescine levels are very low, and 
spermidine is usually found in slightly higher concentration than 
spermine,154 Levels vary with organ and with age in the rat, spermi¬ 
dine levels dropping significantly after one month while spermine levels 
remain relatively constant so that the spermidine:spermine ratio falls 
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sharply from birth.^ 
The polyamine content of chick embryos is highest directly 
after fertilization and again at day 15 of an 18-day incubation, 
closely paralleling the two known RNA peaks, less closely matching 
DNA rises; 141 peak ODC activity in chick embryos occurs at 5 days.158 
Moruzzi, et al., manipulated polyamine levels in chick embryos and 
observed effects on polyribosomal profiles, polymerase activity, and 
nucleic acid label incorporation. They found that increasing polyamine 
concentration by inhibiting amine oxidase with iproniazid led to in¬ 
creased ^H-orotic acid incorporation into both RNA and DNA and into 
larger ribosomes; a decrease in polyamine concentration with increased 
amine oxidase activity led to decreased incorporation. This was es¬ 
pecially true for nuclear DNA and ribosomal RNA. They further found 
that DNA-dependent RNA polymerase activity varied in the same manner with 
I OO 
changes m polyamine concentration. 
Regenerating rat liver--The relationship between polyamines and nucleic 
acid synthesis has been most thoroughly characterized in regenerating 
rat liver after partial hepatectomy, but has also been described in 
conditions of renal^8 and cardiac^’^'* * * * * * 7 hypertrophy in the rat, as well 
as in endocrine target organs, as described later. 
Dykstra and Herbst in 1965 first reported that spermidine levels 
are highest 48 to 72 hours after partial hepatectomy, closely approx¬ 
imating the increased rate of synthesis of RNA in regenerating rat 
7 7 
liver. Raina independently reported a rise in spermidine synthesis, 
measured by 14c_met]1ionine incorporation into spermidine, as early as 
4 to 8 hours after the operation; spermidine was highest at 64 hours. 
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Spermine began to rise only at 16 hours. The ratio of polyamine nitro¬ 
gen to RNA phosphate remained virtually constant through these changes, 
but correlation with DNA phosphate was less close.442 
Work on polyamine turnover rates also supports the view that 
the functions of spermidine in particular are closely allied to those 
of ribosomal RNA, for in the normal and regenerating liver both spermi- 
1 ?? 
dine and rRNA have half-lives of 4 days. 
Interestingly, although Raina and Janne found a marked increase 
in 14c incorporation into spermidine from labelled methionine following 
partial hepatectomy, they could demonstrate no such stimulation of 14c 
incorporation from labelled putrescine under the same conditions.^6>142 
These authors demonstrated a sharp increase in ODC activity in regen¬ 
erating liver, accounting for an accumulation of endogenous putrescine, 
thus explaining increased spermidine synthesis without utilization of 
exogenous putrescine. Putrescine levels closely follow ODC activity 
in this system.^4 Russell and Synder found ODC activity to rise to 22 
times control levels at 16 hours after partial hepatectomy, a dramatic 
rise for a mammalian enzyme. Of five other L-amino acid decarboxylases 
tested in the same livers, none changed in activity. Within one hour 
following operation, the ODC activity tripled, making this the earliest 
enzyme change in regenerating liver; the 16 hour peak in ODC activity 
precedes the peak increases in RNA and DNA synthesis.458 
When rats are divided according to age it becomes clear that the 
ODC rise in regenerating liver is in fact biphasic, the second peak 
nearly coinciding with the first in young rats but becoming more 
fid 
clearly delayed with age. Both increases require protein synthesis. 
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but only the first one is dependent on RNA synthesis, the second appar¬ 
ently being the result of translation from RNA synthesized during the 
first phase.^ Hypophysectomy considerably delays but does not prevent 
the ODC rise in regenerating liver, suggesting that the first peak is 
more hormone-dependent than the second; adrenalectomy, castration, or 
173 
thyroidectomy have no such effect. Hormonal regulation of ODC 
activity in liver and elsewhere is discussed in a later section. 
The response of SAM-decarboxylase to partial hepatectomy in the 
rat is of much lesser magnitude and expressed only much later than the 
ODC stimulation, and older rats do not respond to this stimulus with a 
change in SAM-decarboxylase at all.^^ Synder, et al., were unable to 
label polyamines from l^c-o^i-thine in normal liver because the resting 
rate of putrescine synthesis was so low, while they had no such trouble 
with the -^C-putrescine to spermidine conversion. These two findings 
suggest that in the rat liver SAM-decarboxylase is responsible for main¬ 
taining the constant pool of spermidine, and that the step catalysed 
by ODC is rate-limiting in the unstressed liver. 
Subcellular Effects of the Polyamines 
The discovery of an association between polyamine accumulation 
and nucleic acid synthesis raises the possibility that the relationship 
may be more than coincidence. Polyamines have been reported to affect 
nucleic acid metabolism in a variety of ways. 
A. Macromolecular stabilization 
Nucleic acid phosphate groups are highly acidic, and structures 
containing them are greatly stabilized by polycations. In the T4 phage. 
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putrescine and spermidine account for 40 to 50% of the identifiable 
cation, the remainder being mainly magnesium.^ Watson points out that 
in rapidly growing E. coli, the intracellular magnesium concentration 
is sufficient to neutralize only about half the RNA phosphate negativ¬ 
ity, and that polyamines probably make up the difference. Poly¬ 
amines complex strongly with nucleic acids and polyribonucleotides.^ 
1. DNA stability. Polyamines, especially spermine, stabilize 
DNA against thermal^^»l^O ancj enzymatic degradation, primarily by re¬ 
versibly binding to nucleic acid. ^*^9 
2. RNA stability. As with DNA, spermine is the most effective 
47 119 55 
polyamine in protecting RNA against thermal ’ and enzymatic de- 
37 
gradation, again probably by binding the nucleotide. Polyamines m 
1 08 
high concentrations inhibit ribonucleases, although low levels may 
107 
in fact enhance enzyme activity. 
3. Ribosomal structure. Polyamines promote subunit aggregation 
of ribosomes both m bacteria and m eukaryotes, ’ and 
also promote binding of rat liver ribosomes to endoplasmic reticulum, 
91 
rendering the ribosomes more resistant to ribonuclease. Polyamines 
may also inhibit enzymatic degradation of ribosomes by maintaining the 
3 6 
intact ribosome and preventing ribonuclease release. 
Polyamines can substitute for magnesium in several of its func¬ 
tions iii vitro. In prokaryotes polyamines can replace magnesium, al¬ 
though protein synthesis appears to require the presence of a minumum 
amount of magnesium. It was recently found that during the log¬ 
arithmic phase of growth in E. coli, ribosomal contents rise in con¬ 
cert with spermidine and putrescine, while magnesium levels change 
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little.70 Polyamine stabilization of ribosomes may be a key to the 
177 177 
ability of thermophilic bacteria to function at high temperatures. ^/,x// 
B. Macromolecular function 
1. DNA synthesis. While polyamines have been reported to 
stimulate DNA synthesis in some systems,13,166 they are inhibitory 
in others,1-0,100 the effect apparently varying with the template.1^0 
2. RNA synthesis. Polyamines stimulate RNA polymerase from 
prokaryotes1’00 and mammals17»70584510- in vitro, probably by binding 
the RNA and preventing product inhibition.1,00 Spermidine also stabil¬ 
izes the transcription complex, thereby increasing chain length and 
elongation rate.04,84 
3. tRNA processing. 
a. methylation. Spermine, spermidine, and putrescine pro¬ 
foundly enhance tRNA methylation in vitro, and are even more effective 
than magnesium.100 This effect may be the result of polyamine binding 
4 8 
to tRNA and may involve a competition between polyamine and some 
inhibitor.101 In regenerating liver tRNA methylation does not appear 
167 
to correlate with polyamine levels; however, total cell levels may 
not reflect subcellular distribution of polyamine--as, for example, in 
cultured mouse fibroblast ribosomes where the spermidine:spermine ratio 
rises significantly during exponential growth although the ratio for 
the entire cell remains unchanged."^ 
As SAM serves as a methyl donor in these reactions, it seems 
not unreasonable to speculate about possible interrelationships between 
polyamine synthesis and tRNA methylation. 
' 
12 
b. aminoacylation. Polyamines, especially spermine, en¬ 
hance tRNA aminoacylation in prokaryotes.^^^ The mechanism had 
been thought to involve binding of RNA by polyamines, but recent 
evidence suggests that spermine acts by displacing magnesium from 
tRNA, thereby promoting aminoacylation.162 
4. protein synthesis. Polyamines can reduce the requirement 
for magnesium in protein synthesis by ribosomes from a variety of 
mammalian^®’ ^4 ancj bacterial ^5 28,42,114,182 S0urceS} and while the 
magnesium requirement is in no case eliminated, polyamines are nec¬ 
essary for maximal protein synthesis in several systems.^>^8>^8 
The mechanism seems to involve enhancement of aminoacyl-tRNA binding 
to ribosomes5 183,185 
It is worth noting that for stimulation of tRNA methylation, 
tRNA aminoacylation, and protein synthesis, spermine is more effective 
than spermidine, with putrescine least so; this is precisely the order 
A O 
of avidity of these amines in binding to tRNA. 
C. Other Subcellular Effects 
112 
1. membrane effects. Polyamines protect bacteria, 
bacterial protoplasts^"> ^9 ancj mitochondria"*^ from the effects of 
hypotonicity, by binding to membranes.^>^2,145 Spermidine and spermine 
stabilize rat liver microsomes in vitro, thus enhancing the 2-hydroxyla- 
o r 
tion of estradiol. 
2. effects on carbohydrate metabolism. Spermidine and sper¬ 
mine exert several effects on adipocytes which mimic the effects of 
insulin, including stimulation of glycolysis, inhibition of lipolysis. 
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enhancement of glucose uptake, and blockage of the activation by 
4 4 
epinephrine of adenylate cyclase. These effects are membrane-mediated, 
1 09 
though not through the insulin receptor. 
Polyamines also directly activate certain enzymes in_vitro, 
including phosphoenolpyruvate carboxylase,164 glycogen phosphorylase b 
(in the presence of AMP),1^ and glucose-6-phosphate dehydrogenase.16^ 
D. Inhibitor Studies 
Although the evidence for an association between polyamines 
and growth is diverse and extensive, it is largely circumstantial. 
One cannot conclude from observed in vitro effects of polyamines or 
correlations with other events that they do play an important physio¬ 
logical role, nor can one infer whether any cellular function is truly 
regulatory, or permissive, or whether the relationship is coincidental. 
The very breadth of functions that have been reasonably proposed for 
polyamines seems to preclude any simple assessment of their true func¬ 
tion. Inhibitor studies have offered the hope of defining the role of 
polyamines, but to date have had only mixed success. 
Methylglyoxal bis (guanylhydrazone) (MGBG) inhibits the pro¬ 
liferation of L1210 leukemia cells in mouse hosts, an effect which is 
1 1 O 
counteracted by spermidine. ° The compound was shown to be a specific 
inhibitor of SAM-decarboxylase.1^6 Studies on regenerating rat liver 
failed to reveal inhibition of spermidine accumulation by the drug, nor 
6 3 
any change in nucleic acid synthesis. In mouse parotids, MGBG blocks 
the rise in gland weight and in DNA synthesis in response to stimulation 
by isoproterenol.^ Kay and Pegg reported that MGBG blocked spermidine 
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synthesis in PHA-stimulated lymphocytes, with inhibition of thymidine 
o/: 
incorporation into DNA and phenylalanine incorporation into protein. 
Concentrations of MGBG used in this experiment were shown to be sev¬ 
eral hundred-fold larger than necessary to inhibit spermidine formation, 
39 
and to inhibit directly protein synthesis. Nevertheless, protein 
and DNA synthesis were restored by the addition of spermidine. 
Fillingame and Morris showed that RNA accumulation begins prior to 
rises in polyamine levels in Con-A stimulated lymphocytes, and that low 
concentrations of MGBG blocked spermidine and spermine accumulation 
without altering total RNA synthesis, RNA sucrose-density gradient 
profiles, or the rate of RNA turnover. ^9 However, in their and other 
studies, MGBG led to enhanced ODC activity and to marked rises in 
putrescine levels.39>63 ^he drug has also been shown to prolong greatly 
63 
the half-life of SAM-decarboxylase and to inhibit diamine oxidase. 
Alpha-hydrazino ornithine (aHO) selectively inhibits ODC activ¬ 
ity in vitro^ and blocks putrescine synthesis in cultured rat hepatoma 
cells and in regenerating rat liver without appreciably affecting the 
synthesis of either RNA or DNA.^ The racemic form of aHO, DL-ahydrazino- 
6-amino-valeric acid (DL-HAVA) is a more potent inhibitor of ODC activ¬ 
ity than aHO, and blunts the putrescine rise in isoproterenol-stimulated 
mouse parotid glands; this is associated with inhibition of DNA syn¬ 
thesis and mitotic activity which is reversed by putrescine. The 
authors thus propose a role for putrescine in DNA replication. It 
must be noted however that DL-HAVA prolongs the half-life of parotid 
ODC,^ and that both compounds can enhance ODC activity;^>^3 conclu¬ 
sions from their use should be guarded. 
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Without inhibitors, similar information was obtained by Morris, 
using a mutant of E. coli deficient in arginine decarboxylase and thus 
blocked in one of its pathways of putrescine synthesis and dependent 
on exogenous putrescine for normal growth. During putrescine starvation, 
cell growth rate dropped almost by half, with proportionate decreases in 
elongation rates of RNA and polypeptides, which are corrected by poly¬ 
amine repletion. No changes in RNA size distribution, methylation, or 
turnover were observed. However, this system differs significantly 
from eukaryotes both in polyamine biosynthesis from amino acids and 
in nucleic acid metabolism; no comparable work has been done with 
mammalian cells. 
Hormonal Effects on Polyamine Synthesis 
The discovery in the late 1960's that polyamine levels in sev¬ 
eral tissues depend on hormonal stimuli prompted much work on the reg¬ 
ulation of polyamine metabolism in endocrine target organs. Poly¬ 
peptide hormones (TSH, LH, ACTH, growth hormone, insulin, and glucagon) 
as well as steroids (including estrogens and testosterone), which pro¬ 
mote growth of target tissue, also stimulate ODC activity. The role 
of cyclic AMP (cAMP) in this stimulation appears not to be as clear as 
was once thought. 
A. Target Tissues 
1. Liver. Kostyo in 1966 found that liver spermidine levels 
are reduced after hypophysectomy, but can quickly be restored by the 
administration of growth hormone.^ As in regenerating liver, 
putrescine and spermidine synthesis^ and ODC activity^ are stimulated 
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by growth hormone while spermine content remains essentially un¬ 
changed, 76,95 and SAM-decarboxylase activity rises less and later 
than ODC.80 
The time course for spermidine synthesis from labelled meth¬ 
ionine after a single injection of growth hormone is similar to those 
for enhanced RNA and protein synthesis. ODC activity and nuclear 
RNA polymerase activity rise together after growth hormone adminis¬ 
tration, and they differ from other hepatic enzymes such as tyrosine 
transaminase whose activities are also somewhat elevated by growth 
81 
hormone but which are also affected by fasting and adrenalectomy. 
Other hormones found to enhance hepatic ODC activity include 
hydrocortisone,135 dexamethasone,H and insulin,133 anj to lesser 
degrees glucagon&f3’ 153 and thyroxinel^3; aii give peak enzyme activ¬ 
ity at 3 to 4 hours after stimulation. 
Hormonal stimulation of ODC activity is duplicated by dibutyryl 
cyclic AMP (dbcAMP)H>66 or by phosphodiesterase inhibitors;H>16 ele¬ 
vation of ODC activity by aminophylline or theophylline is preceded by 
a rise in hepatic cAMP.16 Ln vivo studies must be interpreted with 
caution, as dbcAMP and theophylline have been reported to cause release 
of pituitary growth hormone,59 and larger amounts of dbcAMP are re¬ 
quired to elevate liver ODC activity after hypophysectomy. 1^ 
2. Adrenal. Adrenal ODC activity is induced in a dose- 
related manner by adrenocorticotropic hormone (ACTH) in hypophysectomized 
rats.106,149 DbcAMP also gives dose-related ODC stimulation.1^ The 
steroidogenic portion of the ACTH molecule (peptides 1-24) is fully 
effective in stimulating ODC activity, 1*15 but this is not secondary to 
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steroids themselves, for hydrocortisone has no effect, 149 anc[ inhibitors 
of steroidogenesis do not block the ODC response to ACTH. ^6 
A single subcutaneous injection of ACTH causes a rise in 
adrenal cAMP levels within 30 minutes, which fall to normal within 
an hour.105, 149 Richman et al. reported that with increasing doses 
of ACTH, cAMP levels continued to rise beyond those giving maximal 
steroidogenesis; at this higher cAMP range, ODC activity increased in 
parallel with intracellular cAMp!49 (although this finding has been 
106 
disputed ). Thus these higher levels of ACTH might serve to promote 
growth through ODC.149 
Aminophylline or exposure to cold leads to cAMP accumulation at 
30 minutes and ODC stimulation by 4 hours in both the medulla and cortex 
of rat adrenals. Splanchnicotomy abolishes these responses in the 
medulla but not in the cortex.^ 
There is a progressive fall in adrenal ODC responsiveness to 
ACTH after hypophysectomy. ’ 106 Cycloheximide blocks the ODC rise 
with ACTH in rats treated either one or 16 hours after hypophysectomy, 
but actinomycin D was only effective in the one-hour rat, suggesting 
that adrenal ODC induction requires transcription of new protein and, 
in the chronically hypophysectomized rat, translation of mRNA as well.1^6 
Both agents block the stimulation of adrenal ODC by cold exposure or 
aminophylline without affecting the cAMP rise.H' 
The time lag between rises in cAMP levels and ODC activity 
and the inhibition of ODC stimulation with actinomycin D and cyclohexi¬ 
mide suggest that the stimulation represents new synthesis either of 
enzyme protein or of an effector of the enzyme. Direct phosphorylation 
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of the enzyme probably does not occur. ^9 
Growth hormone gives dose-related stimulation of adrenal ODC 
with a time course similar to that with ACTH,105 but does so without 
altering cAMP levels.GH and ACTH are synergeistic in elevating 
ODC activity.105 Thus there may be a second mechanism controlling 
adrenal ODC activity in addition to that mediated by cAMP. 
The only in vitro study of adrenal ODC revealed marked enhance¬ 
ment of enzyme activity in isolated adrenal cells with incubation alone. 
This stimulation was halved by the addition of ACTH, cyclic AMP, or 
corticosterone. The authors proposed that ACTH and cAMP may inhibit 
ODC activity via corticosterone.1^8 
3. Testis. In the rat testis, the specific activity of ODC 
is maximal by 3 days of age, at which time the seminiferous tubules 
contain only Sertoli cells. Spermidine levels, after some delay, 
parallel ODC activity. SAM-decarboxylase, in contrast, rises slowly 
after birth to a plateau corresponding to the time at which spermatids 
mature. The hypothesis that ODC activity resides predominantly in Ser¬ 
toli cells is supported by albumin density gradient separation, which 
leaves nearly all the ODC activity in the dense Sertoli layer.m 
Hypophysectomy dramatically reduces testicular ODC activity, 
which can be restored by FSH, LH, or testosterone.m Stimulation of 
ODC activity by FSH and LH can be mimicked by cAMP but for a briefer 
period; cycloheximide blocks the effects of these latter three 
146 agents. 
4. Prostate. The prostate is unique among organs in that it 
secretes large amounts of polyamines in semen, and therefore has the 

19 
highest specific content of spermidine and spermine. 193 > 194 
Castration reduces, and testosterone fully restores, polyamine 
levels and ODC activity in rat ventral prostate. 1^3,135 Spermidine is 
here the most labile of the polyamines,1^5 its changes correlating 
I 07 
well with changes in RNA levels, although time-sequence studies 
suggest that this more likely reflects a coupling between RNA and 
polyamine biosynthesis than a causal relation.193 SAM-decarboxylase 
activity varies with the same time course and, unlike in other organs, 
to the same degree as ODC activity with castration, hypophysectomy, 
and testosterone. Spermidine levels behave in seminal vesicles as in 
prostate. 
5. Ovary. Adult rats normally exhibit cyclic changes in 
Q Y 
ovarian ODC activity, which rises on the afternoon of proestrus. ° 
This rise can be reproduced by parenteral Lh69?88,93,99,117 or 
HCG; ’ 5 J further , the normal cyclic elevation in ODC activity 
can be prevented by prior injection of antiserum to LH^ or of pento- 
O O 
barbital, which blocks the release of LH from the pituitary. This 
Q Y 
stimulation is specific for gonadotropins. As in other stimulated 
organs, ODC activity peaks at 4 hours after gonadotropin admin¬ 
istration. 88,93,99 
Luteotropin stimulation of ODC activity can be duplicated with 
prostaglandin E2, but this may be due to the release of LH seen in vivo 
after administration of the prostaglandin.^ The rise in ODC activity 
after LH or HCG can be prevented by pretreatment with cycloheximide 
8 S 11 7 o o 
antinomycin D ’ and, for LH, with puromycin as well. 




cycle and after LH; it barely doubles with a dose of HCG sufficient 
igz 
to give 12-fold elevation of ODC activity. 
6. Uterus. In ovariectomized rats, estradiol causes signif¬ 
icant elevation of uterine spermidine, paralleling rises in DNA con¬ 
tent. 1^3 uterine ODC activity rises to peak levels 4 hours after 
o /: o-7 
parenteral 173-estradiol ’ but not if cycloheximide or puromycin is 
87 
administrered two hours after estrogen. Non-steroidal estrogens in- 
8 7 
eluding diethylstilbestrol induce ODC as well. The stimulation by 
173-estradiol is accompanied by no changes in cAMP levels. 
ODC activity changes cyclically in the rat uterus, being highest 
S7 87 87 
at proestrus, ’ ' paralleling estrogen levels. ' Polyamine levels and 
polysome aggregation are also greatest during proestrus, but a causal 
relationship is argued against by the rapid fall of the latter one day 
5 7 
earlier than the former. 
Both 173-estradiol and DES give marked enhancement of oviduct ODC 
activity at 4 hours. Hypophysectomy and castration do not alter this 
response, but it is reduced by 80% with cycloheximide. The stimulation 
is also seen in vitro with incubated oviducts, with complete inhibition 
by cycloheximide. Progesterone gives a small elevation of oviduct ODC 
activity in vivo.26 
7. Mammary tissue. Lactation in the rat is accompanied by 
elevations in mammary ODC and SAM-decarboxylase activities, and by a 
rise in the spermidine:spermine ratio which parallels rises in RNA 
content.156 Cell differentiation and milk protein synthesis in mammary 
tissue iii vitro depend on a combination of insulin, glucocorticoid, and 
prolactin;-^-30 the latter process is preceded by 3-fold elevations in 
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spermidine. Spermidine, but not putrescine, spermine, or magnesium, 
can replace hydrocortisone required for milk protein synthesis. Inhib¬ 
ition of spermidine synthesis by MGBG also blocks the synthesis of milk 
proteins, which can be restored by exogenous spermidine.128,130 with 
such in vitro systems, insulin has been shown to stimulate ODC activ¬ 
ity, ^ insulin with hydrocortisone to stimulate SAM-decarboxylase activ- 
tivity,130 and prolactin to stimulate the activity of arginase in these 
cells with no urea cycle.The stimulation of arginase probably serves 
to supply ornithine for polyamine biosynthesis, for in arginase-poor 
medium lactogenesis does not occur but can be reinstated by adding 
ornithine, putrescine, or spermidine.^^ It thus appears clear that 
polyamines play an important role in protein synthesis in this system. 
Incubation of mammary tissue leads to an early transient rise 
in ODC activity which is independnet of hormonal stimuli (though en¬ 
hanced by hormones) and is associated with a brief elevation of cAMP. 
A second ODC peak at 12 hours depends on insulin and prolactin. The 
second peak requires both transcription and translation, though control 
of the first peak is post-transcriptional.-*^1 Insulin and prolactin 
do not affect cAMP levels despite enhancement of ODC activity with 
these hormones, and the two are additive in effect with dbcAMP,-*^ 
again suggesting a cAMP-independent pathway for enzyme stimulation. 
Epidermal growth factor also stimulates mammary ODC activity.*^ 
Prolactin stimulates ODC activity in rat kidney, adrenal, liver, 
and to some extent thymus and heart, in vivo; this finding lends sup¬ 
port to the view that the hormone has several target tissues.147 
8. Epidermis. Edpidermal growth factor is a polypeptide iso¬ 




stimulate the proliferation of epidermis and possibly other epithelia, 
ft R 
and thus is a hormone by Huxley's definition. One parameter of its 
biological activity is its stimulation of ODC activity in mouse skin 
in vivo; it also causes a transient, translation-dependent rise in ODC 
1 7 f) 
activity in cultured chick embryo epidermis. /D ODC activity parallels 
DNA synthesis in mouse hair follicles during normal cyclic hair growth 
and when stimulated by plucking the hair.-*-40 
9. Kidney. Renal ODC activity varies diurnally in the rat, 
corresponding to variations in plasma corticosteroids, although vari¬ 
ations in growth hormone secretion were not measured. Hypophysectomy 
reduces enzyme activity to a constant low level which can be restored 
best by growth hormone, but also by ACTH and cortisol. Thus renal ODC 
activity is dependent primarily on growth hormone, and probably on corti¬ 
costeroids as well 2^^ 
10. Thyroid. A single injection of TSH results in marked stim¬ 
ulation of thyroid ODC activity peaking at 4 to 6 hours.^^5150,202 
This stimulation is specific, ^02 dose-related,-*-^0 and inhibited by 
cycloheximide and actinomycin d. 1^0,202 The half-life of the thyroid 
enzyme as estimated by the decline in activity following cycloheximide 
is about 15 minutes.-*--*-^ Hypophysectomy blunts this ODC response to 
202 
TSH. Inhibitors of prostaglandin synthesis such as indomethacin 
202 
inhibit the rise in ODC activity with TSH in a dose-related 
fashion-*^ with diminution in thyroid prostaglandin levels, but this 
inhibition is not overcome by exogenous PGE2, nor does this prostaglandin 
stimulate ODC activity in thyroids of normal rats in doses sufficient to 
stimulate adrenal ODC activity.The ODC stimulation is also inhibited 
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by the microtubule antagonists colchicine and vinblastine. There 
is recent evidence that thyroxine and triiodothyronine diminish the 
ODC response to TSH, representing a possible 'short-loop' negative 
1 99 
feedback as part of thyroid regulation 
Aminophylline or dbcAMP alone are unable to stimulate ODC 
1 so ?n? 
activity, ’ but in combination gave 12-fold stimulation as re¬ 
ported by Zusman and Burrow,202 although another group using identical 
dosages observed only minimal elevation in ODC activity. ^5,150 
Treatment with goitrogens leads to increases in thyroid ODC 
activity with a peak at 2 to 4 days; enzyme activity declines there¬ 
after despite continued elevation of serum TSH.^° Putrescine and 
spermidine levels rise until the seventh to tenth day of treatment, 
spermine remaining constant. The spermidine:spermine ratio closely 
matches the RNA:DNA ratio. SAM-decarboxylase activity rises with 
treatment with methylthiouracil, though the increase is much less than 
that of 0DC.H° 
Thyrotropin-releasing hormone gives dose-related stimulation 
of ODC and SAM-decarboxylase activities in the thyroids of intact rats.^^ 
B. Role of Cyclic AMP 
It is now clear that in a number of tissues the stimulation of 
ODC activity is mediated by cyclic AMP. The administration of exogenous 
dibutryrl cyclic AMP leads to elevations in ODC activity in rat liver, ^->66 
149 . 13S 13° 
adrenal, ‘ and testis, as well as in quail oviduct with the same time 
1 39 
curve as stimulation with non-steroidal hormones. DbcAMP has the 
same effect in vitro with cultured hepatoma,^2 glioma,^ and baby hamster 
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kidney^1 cells. Further, polypeptide hormones such as ACTH,^5105,148 
Tsh}150,202 glucagon,^’ FSh}^3,135 and LH,^>93,99,117,123,135 known 
to affect cell metabolism through increases in cAMP levels, also stim¬ 
ulate ODC activity in their target organs. Where the time course has 
been examined, cAMP elevations invariably precede rises in ODC activ¬ 
ity, as seen in rat adrenal after ACTH1^ > 105»and in rat liver, 
1 ft 
kidney, and adrenal after aminophylline or theophylline. In synchron¬ 
ized Chinese hamster cells, elevation of cAMP levels in late G^-early S 
phase are followed by stimulated ODC activity peaking in mid-S phase, 
with subsequent accumulation of polyamines during late S-G2. OL 
On the other hand, steroids appear to control ODC activity via 
mechanisms independent of cAMP. In the rat uterus, 178-estrodiol stim¬ 
ulates ODC activity without affecting cAMP levels, although ODC activ¬ 
ity is sensitive to cAMP elevations as well, as evidenced by the rise 
in ODC activity in the same system with isoproterenol, a known stimu¬ 
lant of uterine adenylate cyclase. The effect of isoproterenol on 
201 
ODC, but not that of estradiol, is blocked by propranolol. Cyclic 
AMP, dbcAMP, 173-estradiol, and diethylstilbestrol all enhance ODC 
activity in quail oviduct, but the response to estrogens is higher and 
more prolonged than the effect of the nucleotide (although in this 
experiment only one concentration each of cAMP and dbcAMP was tested). 
Dexamethasone and dbcAMP stimulate ODC activity in cultured 
rat hepatoma cells, but while the stimulation with dexamethasone is 
blocked by actinomycin D (and not by spermine), the stimulation with 
cAMP is not blocked by actinomycin D (and is prevented by spermine) 
Thus dexamethasone seems to enhance ODC activity in this setting through 
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a mechanism different from cAMP, the latter apparently acting at a post- 
transcriptional level. 
Further, insulin, which lowers hepatic cAMP levels, ^31 stim¬ 
ulates liver ODC activity. 33 Insulin enhances ODC activity in baby 
hamster kidney cells^ and, when combined with prolactin, insulin 
elevates ODC activity in mammary explants without altering cAMP 
levels,although in both systems the response to insulin is enhanced 
by the addition of dbcAMP.>131 
Thus, most polypeptide hormones appear to stimulate ODC activ¬ 
ity through the mediation of cyclic AMP, while steroids and insulin do 
so by other means. In one preliminary report, dbcAMP in a dose suf¬ 
ficient to increase hepatic glucose output, reduced ODC activity in 
perfused rat livers, Responses to cAMP derivatives are usually 
highly dose-dependent!31 and this confusing result might be explained 
by the choice of dose. 
Thyrotropin and Thyroid Metabolism 
The function and growth of thyroid follicular cells are con¬ 
trolled primarily by circulating thyrotropin (thyroid stimulating 
hormone, TSH), a glycoprotein secreted by the anterior pituitary. This 
hormone binds specifically to receptor sites on the thyroid plasma 
'Z O 
membrane and activates adenylate cyclase, resulting in elevation 
of cAMP concentration together with activation of protein kinase. 
A large body of evidence supports the view that many of the effects 
of TSH on the thyroid cell are mediated by cAMP. Interpretation 




variability in time responses of cells within a thyroid to a single 
administration of TSH; by the differing responsiveness of thyroid cells 
from various species to a given stimulus; and occasionally by the dif¬ 
fering effects of small and large doses of TSH. Nevertheless, many 
stimulatory effects of TSH have been well characterized both in vivo 
and in vitro. D 
Role of Cyclic AMP 
The earliest change induced by TSH is an increase in thyroid 
cAMP content, seen in beef thyroid slices within three minutes of incu- 
45 188 
bation, and within ten minutes in rat thyroid lobes and calf 
thyroid cells. Doses of TSH which enhance cAMP accumulation are 
usually in the range at which other effects of TSH are seen,’^5,46,192 
although in some systems TSH continues to elevate cAMP levels at doses 
above those needed to produce colloid droplet formation, iodide re¬ 
lease, and other physiologic effects;^>192 for exampie, in incubated 
mouse thyroids, colloid droplet formation is maximal at 3 mU/ml TSH, 
while cAMP levels continue to rise with increasing TSH concentrations, 
peaking at 30 mU/ml. The role of this further accumulation of cAMP 
is not known. 
The elevation of cAMP levels is due to activation of adenylate 
cyclase, which has been observed in dog thyroids within three minutes 
of TSH injection in vivo.^^ phe dose-response curve for TSH binding 
to thyroid plasma membrane virtually coincides with the one for 
adenylate cyclase activation; both are half-maximal at about 15 mU/ml 
38 and maximal at 75 mU/ml. 
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Cyclic AMP is thought to act intracellularly through the acti¬ 
vation of protein kinases, with dissociation of the catalytic and reg- 
? O 
ulatory subunits. Cyclic AMP-dependent protein kinases have been 
demonstrated in thyroid homogenates, and behave similarly to kinases 
from other tissues. ^4 ppe dose-responses of protein kinase activa¬ 
tion and cAMP accumulation with TSH are compatible with the proposed 
mechanism. To date, substrates for protein kinase have not been 
identified in the thyroid.38 
Cyclic GMP (cGMP) appears to be less stimulated than cAMP by 
TSH, and is probably less important in mediating its effects. Thyro¬ 
tropin seems to affect more the intracellular localization of cGMP 
than its levels, with cGMP redistributing to cytoplasm from membranes 
upon stimulation. Cyclic AMP by contrast appears to be less affected 
in its distribution. It is possible that CGMP is involved in the reg¬ 
ulation of thyroglobulin iodination.38 
Effects of TSH on Thyroid Activity 
Within minutes of injection with or incubation in TSH, and to¬ 
gether with or soon after the rise in cAMP levels, there is enhancement 
of iodide organification, iodothyronine synthesis, thyroxine secretion, 
pseudopod formation, and colloid endocytosis. Thyrotropin also rapidly 
stimulates energy production, as reflected in glucose uptake, lactate 
formation, mitochondrial oxidative metabolism (which accounts for 80% 
of thyroid ATP production) and incorporation of glucose carbon into 




inhibitors and mimicked by dbcAMP*. These early effects of thyro¬ 
tropin are all unaffected by the presence of inhibitors of protein or 
RNA synthesis.^ 
TSH also evokes less rapid responses in the thyroid cell. 
Active iodide transport, which at first is in fact inhibited by TSH, 
is ultimately stimulated after a delay of 2 to 4 hours, and the stim¬ 
ulation is prevented by cycloheximide or actinomycin D. Both the 
lag period and the effect of inhibitors suggest that activation of the 
iodide pump requires synthesis of new protein from newly transcribed 
9 ^ 
RNA. Thyrotropin also stimulates the incorporation of inorganic 
90 
phosphate into membrane phospholipid.' While biochemical evidence 
of enhanced RNA ’±z- and protein synthesis is present within one hour, 
interpretation of these findings is complicated by nonspecific uptake 
of labelled precursors and endocytosis of thyroglobulin. Nevertheless, 
microscopic evidence of synthetic activity appears after 2 to 4 hours 
of stimulation, and includes an increase in the number of clustered 
membrane-free ribosomes, dilation of the cisternae of the endoplasmic 
reticulum, greater development of the Golgi apparatus, and augmented 
cell height. Some traces of enhanced synthetic activity, such as the 
synthesis of lysosomal enzymes, persist after the rapid secretory 
32 responses are no longer evident. 
Kerkof and Tata proposed in 1969 that the slower biosynthetic 
responses to TSH are not mediated by cAMP, while the rapid effects 
*0ne exception: low concentrations of TSH inhibit glucose 
oxidation through the pentose phosphate pathway, though higher con¬ 
centrations cause stimulation; the inhibition, but not the stimulation, 
appears to involve cAMP.46 
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are.^ However, dbcAMP does reproduce the enhancement by TSH of iodide 
93 197 
transport, which requires both transcription and translation; 5 it 
2 
mimics the stimulation of nuclear RNA polymerase in pig thyroid slices, 
and it reproduces the effect of TSH on leucine incorporation into pro¬ 
tein. The stimulation by TSH of protein synthesis in beef thyroid 
cells in vitro has in fact been shown to consist of two phases: (a) an 
'immediate' stimulation seen within 30 minutes of TSH administration and 
disappearing promptly when TSH is removed, which is not affected by in¬ 
hibitors of transcription, and (b) a 'delayed' phase occurring after one 
to two hours and persisting after thyrotropin is withdrawn, which is 
completely dependent on RNA synthesis. Both effects are reproduced in 
all respects by dbcAMP.168 
Chronic stimulation of the thyroid with daily injections of thyro¬ 
tropin leads to cell proliferation to provide for continued production 
of thyroid hormone. Cell mass and number increase. DNA content per 
cell is elevated, reflected microscopically in an increased number of 
polyploid cells. The follicle lumen decreases markedly in size despite 
an augmented thyroglobulin synthesis, reflecting an increased thyroglobulin 
turnover rate. This, together with an increase in cell size, gives an 
elevated cell:colloid ratio, a useful index of stimulation. The vascu- 
T O 





Purpose of This Study 
While many of the effects of thyrotropin on thyroid economy have 
been characterized, the mechanisms by which they are brought about remain 
unclear. This is especially true for the growth-promoting aspects of 
TSH stimulation, which include synthesis of thyroglobulin as well as 
of cellular constituent proteins, nucleic acids, and phospholipids. A 
better knowledge of this regulation could have potential significance for 
our understanding of nontoxic goiter and thyroid neoplasia, both of which 
are common. As polyamines are associated with conditions of growth in 
other organs, and as they can stimulate RNA and protein synthesis in 
cell-free systems, it is possible that polyamines are involved in the 
regulation of growth in the thyroid as well. 
In vivo work on thyroid ODC has demonstrated stimulation of the 
enzyme by TSH. One laboratory has shown stimulation with dbcAMP and 
aminophyl1ine, although this has not been confirmed. Such studies 
are complicated by pharmacologic effects of nucleotides on the pituitary^ 
1 97 
and blood vessels. 
In the present study, we have investigated in vitro the role of 
cAMP in the stimulation of ODC activity by TSH. We have further explored 
a possible function for this stimulation by studying the temporal rela¬ 
tionship between the elevated ODC activity, raised polyamine levels, and 





Methods and Materials 
Male Sprague-Dawley rats weighing 200 g were obtained from Charles 
River Laboratories. The thyroid glands were removed and randomized with 
4 to 12 lobes placed in each beaker. The lobes were preincubated in 5 ml 
Krebs bicarbonate buffer (KRB) for 15 minutes and then incubated for 1-7 
hours in KRB with various agents, in a Dubnoff metabolic shaker at 37 C, 
in a 95% 02/5% CO2 atmosphere. Quantitive bacterial determinations of 
the media were made at intervals up to 7 hours, and no significant con¬ 
tamination occurred. Following incubation, thyroids were homogenized in 
appropriate media (specified below) with a mechanically drive Teflon pestle 
in a Potter-Elvehjem tube. Homogenates were then centrifuged at 4 C, and 
the supernatants assayed for ODC activity or polyamines. For ODC assay, 
4 lobes representing 40-60 mg of tissue were homogenized in 1.4 ml of 
buffer composed of 0.25 M sucrose, 0.5 mM EDTA and 10 mM 2-mercaptoethanol; 
and centrifuged at 100,000 x g for 30 minutes. For polyamine determin¬ 
ations, 8-10 lobes were homogenized in .4 ml of .4 N perchloric acid and 
centrifuged at 1,000 x g for 10 minutes. 
Enzyme Assay 
ODC activity was assayed by measuring ^C02 produced from DL- l-l^c 
158 
-ornithine as described by Russell and Snyder and modified by Chen, 
20 
et al. as follows: the assay mixture contained 0.6 mM DL-orithine, 
0.1 mM pyridoxal-5-phosphate, 25 mM Tris-HCl buffer (pH 7.88 at 37 C), 
13 nmoles mercaptoethanol, and 100 yl of supernatant representing .06-0.2 
mg protein, in a final volume of 215 yl. Within this range of protein 
concentration, ODC activity was linear with thyroid protein concentration. 
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Ornithine was prepared for assay by acidification to 0.1 N HC1, 
heating on a rotary evaporator under vacuum to 54 C for 30 minutes and 
redilution to 0.01 N HC1, to remove a volatile contaminant which other¬ 
wise gave high assay blanks. Cold ornithine was added with dilution, 
prior to assay, to give a final specific activity of 5.8 mCi/mole. 
Decarboxylation was carried out in #2057 Falcon tubes, with 
a polyethylene well containing 0.2 ml of 1:2 monoethalolamine:ethylene 
glycol monoethyl ether suspended from the stopper by a needle. Decar¬ 
boxylation was linear with time for up to 2 hours of incubation; 
assays in the present study were incubated for 90 minutes at 37 C in a 
shaker bath. The reaction was stopped by injection of 0.4 ml 2 N 
citric acid through the needle. After agitation for an additional 60 
minutes at 37 C, each well was removed, placed in 15 ml Aquasol (New 
England Nuclear) and counted on a Packard Tri-carb or a Searle Mark II 
scintillation counter. 
The amount of ^C02 released from substrate in tubes with no 
enzyme was subtracted from the value for all other samples. Picomoles 
of ^^C02 released from the L-isomer only was calculated. Enzyme 
activity was expressed as picomoles ^^C02 released per milligram of 
protein per hour of assay incubation. Protein determination was by 
the Folin-Lowry method^^ using a least-squares calculation for a BSA 
standard curve. 
ODC activity was measured between pH 6.6 and 9.9 and found to 
be maximal from 7.7 to 8.1. Maximal ODC activity was seen at 48 C. 
Kinetic studies reproducibly demonstrated a Km for ornithine of 0.12 
mM, closely comparable to the ODC observed in other mamalian systems 
• . 
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though at variance with the only other Km reported for the thyroid 
enzyme. Our samples was assayed at pH 7.88, 37 C and .6 mM DL- 
ornithine. 
Polyamine Assay 
Tissue levels of putrescine, spermidine, and spermine were 
29 
determined by dansylation according to the method of Dion and Herbst. 
PCA spernatant (0.2 ml) was added to <$„4 ml of dansyl chloride (30 mg/ml 
acetone) and 18.5 mg anhydrous Na^CO^. After 16 hours in the dark at 
room temperature, 0.1 ml of proline (100 mg/ml ^0) was added for 30 
minutes to convert excess dansyl chloride to dansyl proline. Dansyl 
derivatives were extracted into 0.5 ml benzene, and 10 yl of the 
benzene layer was spotted onto 250 ym Silica gel TLC plates which 
had been heated to 100° for one hour prior to spotting. Standard 
samples of all three amines were spotted on each plate as well. 
Plates were run twice with 2:3 ethylacetate/cyclohexane (v/v) in the 
dark, and sprayed immediately with 1:4 triethanolamine/ethylene glycol 
(v/v). Plates were dried in a dark vacuum for 16 hours and allowed 
to equilibrate to atmospheric pressure for one hour before scanning 
on a Turner 111 fluorometer with TLC scanner. Blanks were scanned 
between the putrescine and spermidine spots and were sub tracted from 
values for each sample. The area under each peak (determined by 
weighing the peak) was proportional to the amount of dansyl amine at 
that spot between 0-5 nmoles for putrescine and 0-20 nmoles for sper¬ 
midine and spermine. The assay had a reproducibility of ±11.7% for 
putrescine, 14.2% for spermidine, and 13.7% for spermine. Tissue 
' 
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levels were expressed as nmoles/g of tissue weighed after incubation. 
Medium was lyophilized, solubilized in 0.4N per perchloric acid, and 
assayed as above. 
RNA Synthesis 
For those experiments in which RNA synthesis was measured, 
thyroids were incubated as above with ^H-uridine (10 yCi/ml) added to 
the incubation medium. The pellet remaining after PCA centrifugation 
was washed 3 times in 5% tricholoroacetic acid and resuspended in 0.2 
i 
3 . . 
ml 1 N NaOH; 20 yl aliquots were counted in Aquasol. H-undme 
incorporation into RNA was expressed as cpm per g of tissue. 
Materials 
TSH was kindly supplied by the National Institutes of Health 
(NIH-THS-B7). 3-Isobutyl-l-methyl xanthine was purchased from the 
Aldrich Chemical Company. Dibutyryl 3'5' cyclic monophosphoric acid, 
actinomycin D, puromycin, putrescine, spermidine, spermine, dansyl 
choloride, and ipronizaid phosphate were purchased from Sigma Chemicals 
Uridine-6-H^ (24.2 Ci/nmole, lot #908-053) and DL- 1-^C - ornithine 
monohydrochloride (lot #822-176) were obtained from New England Nuclear 
Results 
Stimulation of Thyroid ODC In Vitro 
Incubation of rat thyroid lobes with 50 mU/ml of TSH resulted 
in a 3 to 5-fold stimulation of ODC activity at 5 hours (p< .001). 
The addition of 0.5 mM 3-isobutyl-l-methyl xanthine (MIX), a potent 




peak ODC activity occurring usually at 5 hours, and occasionally at 
6 hours (Figure 2). Incubation with MIX alone stimulated ODC activ¬ 
ity, with stimulation by 0.5 mM MIX not significantly different from 
stimulation by 50 mU/ml of TSH at 5 hours of incubation. All incuba¬ 
tions with MIX were at a concentration of 0.5 mM. The small rise in 
control activity with time (Figure 2) is unexplained, but a similar 
2 6 
rise was observed by Cohen, et al., in chick oviducts in vitro. 
Pilot experiments with calf thyroid slices showed the ODC 
activity in this tissue to rise only two to three-fold when incubated 
with TSH and MIX. Further studies with this species were not pursued. 
The stimulation of rat thyroid ODC activity by TSH was dose- 
related: 5 mU/ml of TSH significantly elevated ODC activity over 
control, and maximal stimulation was seen with 25 mU/ml (Figure 3). 
All subsequent incubations with TSH were done at a concentration of 
50 mU/ml. 
Incubation of thyroids with dibutyryl cyclic AMP (dbcAMP) re¬ 
sulted in dose-related stimulation of ODC activity up to a concentra¬ 
tion of 2 mM. There was no stimulation over control at 5 mM dbcAMP, 
as confirmed by several repetitions (Figure 4). The stimulation of 
ODC activity by 1 mM dbcAMP was not enhanced by the addition of MIX. 
Effects of Inhibitors of RNA and Protein 
Synthesis on Thyroid ODC Activity 
The addition to 0.2 mM puromycin or 10 yg/ml actinomycin D to 
the preincubation and incubation medium inhibited stimulation of ODC 
activity in response to TSH and MIX (Figure 5). Puromycin completely 




thyroids. A concentration of 1% ethanol was required to solubilize the 
actomycin D; this concentration was found to eliminate the ODC activity 
in the incubated control and to attenuate the ODC response to TSH and 
MIX. Thus while the data show inhibition of ODC activity by actinomycin 
D, it is impossible to distinguish complete from incomplete inhibition. 
Stimulation of Thyroid Amine 
Levels in vitro 
Thyroid lobes contained basal levels of about 300 nmoles/g of 
spermidine and spermine and one-tenth as much putrescine. Tissue 
levels of all three amines did not rise before the fifth hour of in¬ 
cubation with TSH and MIX. At six hours, a three-fold increase in 
tissue putrescine levels was observed (p <.05), together with marked 
leakage of putrescine into the medium, when thyroids were incubated 
in TSH and MIX (Figure 6). Spermidine and spermine were not signif¬ 
icantly elevated at 6 hours. Both control and stimulated samples in 
this experiment were incubated with 5 mM iproniazid, an amine oxidase 
inhibitor, to prevent polyamine degradation. 
Time Course of Stimulation of ODC Activity, 
Putrescine Content, and RNA Synthesis 
Figure 7 illustrates the time course for ODC activity, putres¬ 
cine levels, and ^H-uridine incorporation into RNA in a representative 
incubation with TSH and MIX. ODC activity rose at 4 hours, peaked at 
5 hours, and declined thereafter. Although these samples were incubated 
without iproniazid, putrescine levels were significantly elevated over 
controls at 6 hours, following the ODC peak (p<.05). Spermidine and 
spermine levels were again not significantly elevated during this time 
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period. Putrescine leakage into the medium closely paralleled tissue 
levels. RNA synthesis as measured by incorporation of tritiated uri¬ 
dine into acid-insoluble material, rose significantly at the seventh 
hour. 
Discussion 
This is the first report of stimulation of thyroid ODC in vitro. 
Our results match the earlier in vivo observations that a single in¬ 
jection of TSH in rats yields peak activity of thyroid ODC 4 to 6 
hours later.H6,150,202 The 3 to 5-fold rise in vitro is comparable 
to the degree of stimulation observed in vivo in hypophysectomized 
202 
rats, but significantly less than that found with intact rats. 
Role of cAMP in ODC stimulation 
Dibutyryl cyclic AMP has been shown to stimulate ODC activity 
13" 
in the adrenals of hypophysectomized rats,149 cultured mammary tissue, 
202 
and when given with aminophylline in thyroids of normal rats. 
Enzyme activity in livers of intact rats was stimulated by dbcAMP,^’^ 
but not consistently in livers of hypophysectomized rats. As dbcAMP 
is known to cause release of pituitary hormones'^ and to alter blood 
flow, in vivo studies must be interpreted carefully. Further, 
there are systems in which ODC stimulation occurs without changes in 
201 
tissue cAMP levels. Insulin, which lowers cAMP levels in target 
tissues, stimulates ODC activity in liver^’l^ and in mammary ex- 
2 
plants. Thus in some systems induction of ODC activity appears to 
involve a mechanism independent of cAMP. 
Sutherland^! has suggested four criteria by which to judge a 
' 
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claim that a given hormone produces a given effect through the media¬ 
tion of cAMP: 
1. the hormone should stimulate adenylate cyclase in broken 
cell preparations; this effect should be specific for that hormone; 
2. the hormone should elevate cAMP levels in intact cells; 
this again should be a specific effect, detectable at the smallest 
dose of hormone producing the physiological response and occurring as 
early as or earlier than that response; 
3. the response to the hormone should be potentiated by 
phosphodiesterase inhibitors; 
4. exogenous cAMP or one of its soluble derivatives should re¬ 
produce the response. 
TSH specifically activates adenylate cyclase in thyroid plasma 
7 Q 
membrane preparations. ° Thyrotropin also raises intracellular cAMP 
46 19? 
levels, beginning at 0.25-0.3 mU/ml in the beef thyroid; 5 “ the 
first siginficant effect on ODC activity in the rat thyroid is seen at 
5 mU/ml (although this is not strictly comparable because of species 
variation, differing TSH preparations, and probably other experimental 
differences as well). The effect of thyroid ODC activity is specific 
for TSH^O- and is markedly enhanced by the addition of MIX. Finally, 
the ODC response is reproduced in a dose-related manner by exogenous 
dbcAMP. The ineffectiveness of 5 mM dbcAMP is not surprising, for 
Sutherland remarks that dose-responses to exogenous cAMP are character¬ 
istically "bell-shaped over a relatively narrow range," probably be¬ 
cause of toxic effects of the nucleotide at supraphysiologic concen¬ 
trations;'*'^ such behavior has been seen before in the thryoid.^ Thus 
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the stimulation of ODC activity appears to satisfy all of Sutherland's 
criteria. 
ODC activity continues to rise at TSH concentrations signif¬ 
icantly above those required for most physiological responses. This, 
70 
however, is also the case for cAMP in most species, with peak cAMP 
levels in the mouse thyroid, for example, occurring at 30 mU/ml of 
TSH. The stimulation of ODC activity might then be a purpose for 
such previously unexplained peak cAMP levels. A similar situation 
exists in the adrenal, where ODC activity and cAMP accumulation are 
still stimulated at ACTH levels far beyond those needed for maximal 
■ , • 149 steroidogenesis. 
The elevation of putrescine content with ODC activity implies 
that the increase in ODC activity is physiologic rather than an assay 
artifact. Polyamine levels reported here are comparable to those found 
in other rat organs^ >76 if a correction is made for the extracellular 
thyroglobulin content of the thyroid. The accumulation of putrescine 
alone during the 7 hour incubation in the present study is similar to 
the finding in regenerating rat liver that putrescine levels rise by 
2 to 3-fold beginning 4 hours after partial hepatectomy, while spermi- 
7 (S 
dine rises by much less and not until 8 hours. Matsuzaki and Suzuki 
reported elevation of putrescine and spermidine levels in the thyroid 
beginning on the second day of goitrogen treatment. 
The degree of putrescine leakage into the medium was unexpected. 
In the presence of 5 mM iproniazid it is unlikely that this represents 
putrescine produced by the breakdown of oxidized spermidine or sper- 




are spermidine and spermine, and this might explain the elevation of 
putrescine in the medium in the absence of any change in spermidine or 
spermine content of the medium. 
We have found that ODC activity and putrescine levels rise prior 
to an increase in H-uridine incorporation into RNA. Stimulation of 
^H-uridine incorporation has been observed in vitro after one to four 
7 17 1 07 34 
hours of incubation with TSH by several though not all inves¬ 
tigators. In none of these studies was incubation carried out for seven 
hours; it is possible that our methods were too insensitive to detect 
a small earlier change in uridine uptake into RNA. 
Studies using metabolic inhibitors indicate that stimulation 
of ODC activity requires new synthesis of RNA. 1*^,202 It also has been 
proposed that polyamines participate in the regulation of RNA synthesis, 
which was also suggested by our findings. This is compatible with a 
model whereby a small early increase in RNA production might lead to 
a polyamine accumulation which would be followed by greater augmenta¬ 
tion of nucleic acid synthesis. 
Regulation of ODC activity in the thyroid seems to depend on 
synthesis of new protein and RNA^0,202 and the effects of inhibitors 
are confirmed by the present data. However, whether there is actually 
an induction of protein or a change in the activity of ODC is not known. 
In preliminary experiments not reported here, an antibody to partially 
purified hepatic ODC^^ inactivated about 90% of the ODC activity in 
TSH-stimulated thyroid supernatants. Further, radio-iodinated anti¬ 
body appeared to precipitate protein as it inactivated ODC, suggesting 
that TSH stimulation of ODC activity did in fact represent induced 
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synthesis of enzyme protein. 
TSH has several immediate effects on the thyroid such as the 
stimulation of adenylate cyclase and the release of thyroid hor- 
32 200 
mones. ’ Continued TSH stimulation results in additional effects 
93 1 34 
including enhanced uptake of iodide and thyroglobulin synthesis. ’ 
These delayed effects appear to differ from the immediate ones in that 
they require synthesis of protein and RNA. Polyamines might play a 








































































The time course of ODC activity in thyroids incubated with 
50 mU/ml TSH and 0.5 mM MIX (•-) ard in controls (‘-• 
A typical experiment is shown. Each point represents the 








































Effect of varying concentrations of TSH on thyroid ODC 
activity ft 5 hours of incubation. Each point represents 
the mean - 5EM of 3 determinations. 

FIGURE 4 
CDb cAMP] (mM) 
Effect, ot varying concentrations of dbcAMP on thyroid ODC 
activity at 5 hours of incubation. Each point represents 
the mean ± SEM of 3 determinations. Bar graph represents 








































Control TSH + Actmomycin D 
Methyl + TSH 
Xanthine + Methyl 
Xanthine 
Upper figure: Effect of 0.2 niM puromycin on the stimulation 
of thyroid ODC activity hi vitro at 5 hours of incubation as 
compared with stimulated thyroids without inhibitor and con¬ 
trols . 
Lower figure: Effect of 10 yg/ml actinomvcin D on the stim¬ 
ulation of ODC activity as compared with stimulated thyroids 
and controls. 























TSH + Methyl Xanthine 
TISSUE MEDIUM 
Effect of TSH and MIX on putrescine levels in thyroid tissue 
and incubation medium at 6 hours of incubation. All beakers 

























INCUBATION TIME (hours) 
The time course of ODC activity, putrescine levels, and RNA 
synthesis in thyroids incubated with TSH and MIX. 
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